Key Highlights

  • Executed U.S. blood partnerships now cover about 179 fixed-point collection sites, roughly 17% of civilian sites, that collect about 2.4 million units a year.
  • Vitrafy signed Versiti Blood Health on 30 September 2026 and Charter Medical on 2 September 2026, adding to Vitalant and Hoxworth Blood Center.
  • Nine Guardion cryopreservation devices were built in the quarter, with six more due in the first half of FY2027.
  • Cash and term deposits were A$38.3 million at 30 September 2026, after a net operating cash outflow of A$4.9 million.

Vitrafy Life Sciences Limited (ASX:VFY) reported a quarter of partnership signings and device builds for the three months to 30 September 2026, the first quarter of its 2027 financial year. The Melbourne cryopreservation company added Versiti Blood Health to its U.S. civilian blood program, entered the cell and gene therapy market through Charter Medical, and completed the build of nine Guardion devices. It ended the period with A$38.3 million in cash and term deposits.

Third Blood Partnership Lifts U.S. Site Coverage

On 30 September 2026 Vitrafy announced Versiti Blood Health as its third U.S. civilian blood partner, joining Vitalant and Hoxworth Blood Center. The agreement is aimed at advancing no-wash platelet cryopreservation, with two Guardion devices to be placed at Versiti's Blood Research Institute in Milwaukee. Versiti will also supply blood products and resources for validation studies on currently approved cryopreserved products, including plasma, as part of the Guardion medical device listing.

The three executed partnerships give exposure to about 17% of U.S. civilian blood collection sites, covering about 179 fixed-point sites that collect roughly 2.4 million units of blood a year. The work focuses on red blood cells and platelets. Onboarding and workflow mapping were carried out with partners during the quarter, and devices are being deployed in the current quarter.

Cell and Gene Therapy, Conference Data and Advisory Board

On 2 September 2026 Vitrafy announced an agreement with Charter Medical covering its entry into the U.S. cell and gene therapy market. A Guardion device and LifeChain software will be installed at Charter Medical's North Carolina Innovation Hub for cryopreservation and freeze-curve optimisation studies. Separately, testing and validation continued under the agreement with IMV in animal health.

At the AABB Annual Meeting in Atlanta from 17 to 19 October, Vitrafy exhibited the Guardion device and launched its Scientific Advisory Board, drawn from transfusion medicine, cell therapy and clinical research. The USAISR separately presented results of its Phase II in-vitro platelet study, in which a 3% DMSO no-wash protocol produced 94.4% mean post-thaw platelet recovery. The company describes this as independent third-party presentation of the data.

Devices, Device Listing and Leadership

Vitrafy completed the build of nine Guardion devices in Q1 FY27, all earmarked for existing partners and medical device testing. Six more will be built in the first half of FY2027, with deliveries in October and November. Medical device units are due to be manufactured in Australia from early 2027, after listing, and U.S. manufacturing is planned to be operational in the second half of 2027.

Several verification workstreams for the planned U.S. medical device listing are complete and the rest are in progress. Validation studies on blood products, starting with plasma, are about to begin with support from the USAISR and Bio Bridge Global. Listing is expected by the end of the first half of FY2027. A U.S.-based Chief Operating Officer joined, and Jan Gielen was appointed Chief Financial Officer from 1 February 2027.

Cash Flow and Closing Position

Net operating cash outflow was A$4.9 million. Customer receipts were A$0.1 million, with A$0.3 million from government grants and A$0.4 million in interest. Cash expenditure was A$5.7 million, against A$5.6 million in the prior quarter, an average of about A$1.9 million a month, as product development spending fell while manufacturing, validation, testing and marketing costs rose. Cash and equivalents were A$23.2 million, alongside term deposits of about A$15 million. The Appendix 4C shows 4.8 estimated quarters of funding, or 7.9 including the deposits. Payments to related parties and their associates were A$214,000, comprising non-executive director fees and executive director remuneration. The quarter closed with three U.S. blood partners signed, nine devices built and A$38.3 million held.